Lexatumumab, the targeted antibody, shows remarkable hope in the battle against malignant illness. This new therapy selectively attaches to lthe HER3 molecule, which are frequently overexpressed in various tumoral https://bookmark-dofollow.com/story28398888/lexatumumab-an-novel-treatment-for-malignancy